Stoke Therapeutics (STOK) Return on Capital Employed (2019 - 2026)
Stoke Therapeutics' quarterly Return on Capital Employed came in at 47.49% in Q1 2026, down 6048.0% year-on-year from 0.8% in Q1 2025, and down 664.59% quarter-over-quarter from 6.21% in Q4 2025.
Stoke Therapeutics has reported Return on Capital Employed for 8 years, with the latest figure at 47.49% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 6048.0% year-over-year to 47.49%; the trailing twelve-month figure through Mar 2026 stood at 47.49% (down 6048.0% YoY), and the FY2025 full-year result was 7.17%, up 4113.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 47.49%, down from 6.21% in the prior quarter.
- The five-year high for Return on Capital Employed was 12.98% in Q1 2025, with the low at 65.38% in Q1 2024.
- Average Return on Capital Employed over 5 years is 34.13%, with a median of 43.91% recorded in 2023.
- Year-over-year, Return on Capital Employed jumped 7837 bps in 2025 and plunged 6048 bps in 2026.
- Tracing STOK's Return on Capital Employed over 5 years: stood at 44.32% in 2022, then retreated by 27 bps to 56.46% in 2023, then advanced by 26 bps to 41.82% in 2024, then jumped by 85 bps to 6.21% in 2025, then slumped by 665 bps to 47.49% in 2026.
- The last three Return on Capital Employed figures came in at 47.49% (Q1 2026), 6.21% (Q4 2025), and 8.22% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -47.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.49% |
| Dec 31, 2025 | -6.21% |
| Sep 30, 2025 | 8.22% |
| Jun 30, 2025 | 11.28% |
| Mar 31, 2025 | 12.98% |
| Dec 31, 2024 | -41.82% |
| Sep 30, 2024 | -46.80% |
| Jun 30, 2024 | -54.03% |
| Mar 31, 2024 | -65.38% |
| Dec 31, 2023 | -56.46% |
| Sep 30, 2023 | -50.34% |
| Jun 30, 2023 | -45.36% |
| Mar 31, 2023 | -43.91% |
| Dec 31, 2022 | -44.32% |
| Sep 30, 2022 | -39.01% |
| Jun 30, 2022 | -34.60% |
| Mar 31, 2022 | -36.95% |
| Dec 31, 2021 | -37.55% |
| Sep 30, 2021 | -30.79% |
| Jun 30, 2021 | -25.49% |
| Mar 31, 2021 | -20.59% |
| Dec 31, 2020 | -22.33% |
| Sep 30, 2020 | -24.97% |
| Jun 30, 2020 | -21.77% |
| Mar 31, 2020 | -18.73% |
| Dec 31, 2019 | -15.53% |
| Sep 30, 2019 | -12.26% |